# Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine

> **NCT05366296** · PHASE1 · WITHDRAWN · sponsor: **Wuhan Recogen Biotechnology Co., Ltd.**

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **BIOLOGICAL:** A Lyophilized COVID-19 mRNA Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05366296
- **Lead sponsor:** Wuhan Recogen Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07
- **Primary completion:** 2022-09
- **Final completion:** 2023-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** business stragety
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05366296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05366296, "Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05366296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*